MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism

Molecular Therapy

Volumn 19, Issue 6, 2011, Pages 1097-1106

  Leber, Mathias F ^a   Bossow, Sascha ^a   Leonard, Vincent H J ^b   Zaoui, Karim ^a   Grossardt, Christian ^a   Frenzke, Marie ^b   Miest, Tanner ^b   Sawall, Stefanie ^a   Cattaneo, Roberto ^b   Von Kalle, Christof ^a   Ungerechts, Guy ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 7; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE CONTROL; GENE FUSION; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION SENSITIVITY; MEASLES; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROGENY; PROTEIN PROCESSING; TUMOR XENOGRAFT; VIRAL TROPISM; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION;

MEASLES VIRUS; MUS;

EID: 79957889064     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.55     Document Type: Article

References (50)

1. Galanis, E, Hartmann, LC, Cliby, WA, Long, HJ, Peethambaram, PP, Barrette, BA et al. (2010). Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70: 875-882.
2. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
3. Myers, R, Harvey, M, Kaufmann, TJ, Greiner, SM, Krempski, JW, Raffel, C et al. (2008). Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther 19: 690-698. (Pubitemid 352009918)
4. Allen, C, Paraskevakou, G, Liu, C, Iankov, ID, Msaouel, P, Zollman, P et al. (2008). Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 8: 213-220. (Pubitemid 351233714)
5. Ungerechts, G, Springfeld, C, Frenzke, ME, Lampe, J, Parker, WB, Sorscher, EJ et al. (2007). An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 15: 1991-1997. (Pubitemid 350011739)
6. Ungerechts, G, Springfeld, C, Frenzke, ME, Lampe, J, Johnston, PB, Parker, WB et al. (2007). Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fudarabine. Cancer Res 67: 10939-10947. (Pubitemid 350145923)
7. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878. (Pubitemid 44298654)
8. Ungerechts, G, Frenzke, ME, Yaiw, KC, Miest, T, Johnston, PB and Cattaneo, R (2010). Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther 17: 1506-1516.
9. Edge, RE, Falls, TJ, Brown, CW, Lichty, BD, Atkins, H and Bell, JC (2008). A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specifc replication. Mol Ther 16: 1437-1443.
10. Kelly, EJ, Hadac, EM, Greiner, S and Russell, SJ (2008). Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14: 1278-1283.
11. Kelly, EJ, Nace, R, Barber, GN and Russell, SJ (2010). Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 84: 1550-1562.
12. Lee, CY, Rennie, PS and Jia, WW (2009). MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res 15: 5126-5135.
13. Ylösmäki, E, Hakkarainen, T, Hemminki, A, Visakorpi, T, Andino, R and Saksela, K (2008). Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specifc MicroRNA. J Virol 82: 11009-11015.
14. Kefas, B, Godlewski, J, Comeau, L, Li, Y, Abounader, R, Hawkinson, M et al. (2008). microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572.
15. Webster, RJ, Giles, KM, Price, KJ, Zhang, PM, Mattick, JS and Leedman, PJ (2009). Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741.
16. Landgraf, P, Rusu, M, Sheridan, R, Sewer, A, Iovino, N, Aravin, A et al. (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414. (Pubitemid 46970709)
17. Bourhis, JM, Canard, B and Longhi, S (2006). Structural disorder within the replicative complex of measles virus: functional implications. Virology 344: 94-110. (Pubitemid 41818949)
18. Leonard, VH, Hodge, G, Reyes-Del Valle, J, McChesney, MB and Cattaneo, R (2010). Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J Virol 84: 3413-3420.
19. Leonard, VH, Sinn, PL, Hodge, G, Miest, T, Devaux, P, Oezguen, N et al. (2008). Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 118: 2448-2458. (Pubitemid 351949773)
20. Springfeld, C, von Messling, V, Frenzke, M, Ungerechts, G, Buchholz, CJ and Cattaneo, R (2006). Oncolytic effcacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 66: 7694-7700. (Pubitemid 44289228)
21. Cathomen, T, Mrkic, B, Spehner, D, Drillien, R, Naef, R, Pavlovic, J et al. (1998). A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J 17: 3899-3908. (Pubitemid 28333976)
22. Duprex, WP, McQuaid, S, Roscic-Mrkic, B, Cattaneo, R, McCallister, C and Rima, BK (2000). In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fuorescent protein. J Virol 74: 7972-7979. (Pubitemid 30641641)
23. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540. (Pubitemid 351850977)
24. Cattaneo, R (2010). Paramyxovirus entry and targeted vectors for cancer therapy. PLoS Pathog 6: e1000973.
25. Hoffmann, D, Bangen, JM, Bayer, W and Wildner, O (2006). Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther 13: 1534-1544. (Pubitemid 44567150)
26. Blechacz, B, Splinter, PL, Greiner, S, Myers, R, Peng, KW, Federspiel, MJ et al. (2006). Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44: 1465-1477. (Pubitemid 44953652)
27. Penheiter, AR, Wegman, TR, Classic, KL, Dingli, D, Bender, CE, Russell, SJ et al. (2010). Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol 195: 341-349.
28. Msaouel, P, Iankov, ID, Allen, C, Morris, JC, von Messling, V, Cattaneo, R et al. (2009). Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69: 82-91.
29. Peng, KW, TenEyck, CJ, Galanis, E, Kalli, KR, Hartmann, LC and Russell, SJ (2002). Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62: 4656-4662.
30. McDonald, CJ, Erlichman, C, Ingle, JN, Rosales, GA, Allen, C, Greiner, SM et al. (2006). A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 99: 177-184. (Pubitemid 44268265)
31. Li, H, Peng, KW, Dingli, D, Kratzke, RA and Russell, SJ (2010). Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 17: 550-558.
32. Dingli, D, Peng, KW, Harvey, ME, Greipp, PR, O'Connor, MK, Cattaneo, R et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103: 1641-1646. (Pubitemid 38268954)
33. Munguia, A, Ota, T, Miest, T and Russell, SJ (2008). Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 15: 797-806. (Pubitemid 351627364)
34. Studebaker, AW, Kreofsky, CR, Pierson, CR, Russell, SJ, Galanis, E and Raffel, C (2010). Treatment of medulloblastoma with a modifed measles virus. Neurooncology 12: 1034-1042.
35. Allen, C, Vongpunsawad, S, Nakamura, T, James, CD, Schroeder, M, Cattaneo, R et al. (2006). Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain signifcant antitumor activity against gliomas with increased tumor specifcity. Cancer Res 66: 11840-11850. (Pubitemid 46094196)
36. Paraskevakou, G, Allen, C, Nakamura, T, Zollman, P, James, CD, Peng, KW et al. (2007). Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas. Mol Ther 15: 677-686. (Pubitemid 46431987)
37. Allen, C, Paraskevakou, G, Iankov, I, Giannini, C, Schroeder, M, Sarkaria, J et al. (2008). Interleukin-13 displaying retargeted oncolytic measles virus strains have signifcant activity against gliomas with improved specifcity. Mol Ther 16: 1556-1564.
38. Russell, SJ and Peng, KW (2009). Measles virus for cancer therapy. Curr Top Microbiol Immunol 330: 213-241.
39. Junn, E, Lee, KW, Jeong, BS, Chan, TW, Im, JY and Mouradian, MM (2009). Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 106: 13052-13057.
40. Doxakis, E (2010). Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 285: 12726-12734.
41. Kelly, EJ, Hadac, EM, Cullen, BR and Russell, SJ (2010). MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog 6: e1000820.
42. Myers, RM, Greiner, SM, Harvey, ME, Griesmann, G, Kuffel, MJ, Buhrow, SA et al. (2007). Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 82: 700-710. (Pubitemid 350114828)
43. Lun, XQ, Jang, JH, Tang, N, Deng, H, Head, R, Bell, JC et al. (2009). Effcacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 15: 2777-2788.
44. Cathomen, T, Naim, HY and Cattaneo, R (1998). Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 72: 1224-1234. (Pubitemid 28116907)
45. Radecke, F, Spielhofer, P, Schneider, H, Kaelin, K, Huber, M, Dötsch, C et al. (1995). Rescue of measles viruses from cloned DNA. EMBO J 14: 5773-5784.
46. Calain, P and Roux, L (1993). The rule of six, a basic feature for effcient replication of Sendai virus defective interfering RNA. J Virol 67: 4822-4830. (Pubitemid 23215963)
47. Rager, M, Vongpunsawad, S, Duprex, WP and Cattaneo, R (2002). Polyploid measles virus with hexameric genome length. EMBO J 21: 2364-2372. (Pubitemid 34546709)
48. Duprex, WP, McQuaid, S, Hangartner, L, Billeter, MA and Rima, BK (1999). Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fuorescent protein-expressing recombinant virus. J Virol 73: 9568-9575. (Pubitemid 29487112)
49. Mühlebach, MD, Leonard, VH and Cattaneo, R (2008). The measles virus fusion protein transmembrane region modulates availability of an active glycoprotein complex and fusion effciency. J Virol 82: 11437-11445.
50. Toth, AM, Devaux, P, Cattaneo, R and Samuel, CE (2009). Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-defcient measles virus. J Virol 83: 961-968